GLP-2 (TR)

Dual agonists in this class engage both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor with a single sequence. GIP is the other major incretin, released from intestinal K-cells, and its receptor has a different tissue distribution from the GLP-1 receptor — notably in adipose tissue, where GLP-1 receptors are sparse.

Engineering one peptide to activate two related but distinct class B GPCRs is a structural problem rather than a matter of combining two drugs, and the balance of potency between the two receptors is a design parameter that differs between molecules in this class. This item is listed under a coded site name; research support can confirm identity for a specific batch.

Work here concentrates on what the second receptor adds. GIP receptor signalling in adipocytes affects lipid handling in ways GLP-1 agonism does not reach, and whether the combination is additive, synergistic or partly offsetting is an open question that depends on the potency ratio of the particular molecule.

Comparative designs are the norm: a dual agonist is usually run alongside a single-receptor comparator and sometimes a triple, which is why the catalogue carries all three coverage levels. The metabolic research peptides hub sets out how this group divides.

Supplied lyophilised at a higher total mass than most of the catalogue, which makes accurate reconstitution volume more consequential — a small volumetric error at 30mg carries further than the same error at 5mg.

As with the rest of this class, aggregation in solution rather than chemical degradation is the practical risk. Swirl, do not shake; keep solutions cold and freshly prepared. Solvents are listed under reconstitution supplies.